VRX up +1.72% percent Today $VRX High is at 133.39 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
VRX up +1.72% percent Today $VRX High is at 133.39 and the Low 131.65 with current volume of 331,996.

Recent News posted below.

Valeant Pharmaceuticals International VRX other info.
http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/

VRX Valeant Pharmaceuticals International Recent Headline News

Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.66 (+1.15), VRX: 133.65 (+2.56), ACT: 244.26 (+3.64)

Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.14 (+0.50), AGN: 197.66 (+1.15), VRX: 133.65 (+2.56), ACT: 244.26 (+3.64)

Cramer Says Zoetis Could Be Next M&A Target for Ackman, Valeant
at The Street - Wed Nov 12, 10:37AM CST
Bill Ackman has a stake in Valeant Pharmaceuticals, as well as Zoetis, the latter of which may become a takeover target by the former, Jim Cramer says.
ZTS: 43.14 (+0.50), VRX: 133.65 (+2.56)

Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - Wed Nov 12, 10:04AM CST

ZTS: 43.14 (+0.50), T: 35.89 (+0.49), VRX: 133.65 (+2.56), FOSL: 110.26 (-2.22), BBT: 37.51 (-0.16), PFE: 30.62 (+0.20), KORS: 71.48 (+0.48), SUSQ: 13.08 (-0.04)

Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.14 (+0.50), AGN: 197.67 (+1.16), HLF: 37.66 (-0.15), VRX: 133.65 (+2.56), PFE: 30.62 (+0.20), MRK: 59.89 (+0.58), LLY: 67.96 (+0.56)

Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST

AGN: 197.67 (+1.16), VRX: 133.65 (+2.56)

Wall Street Breakfast: Global Banks Fined $3.4B In Forex Probe
Wall Street Breakfast - Seeking Alpha - Wed Nov 12, 5:30AM CST
Economy Japanese stocks scaled seven-year highs this morning on further speculation that Prime Minister Shinzo Abe will postpone a planned sales tax hike and call a general election for December. The Sankei newspaper reported that Abe would...
VRX: 133.65 (+2.56), MDT: 69.51 (+1.01), C: 53.44 (+0.02), WMT: 81.89 (+2.69), RBS: 11.78 (-0.04), UBS: 17.63 (+0.25), NOK: 8.27 (+0.22), YHOO: 50.44 (-0.16), PBR: 10.52 (-0.04), SPY: 204.83 (+0.87), SAP: 66.87 (+0.42), EBAY: 54.43 (+0.37), JPM: 60.62 (+0.06), BHP: 58.13 (-0.05), AAPL: 113.38 (+2.13), BCS: 14.45 (-0.13), FRM: 6.33 (-0.26), COV: 94.21 (+1.33), HSBC: 50.21 (-0.01), FRGI: 56.04 (-0.63), ZTS: 43.14 (+0.50), DLA: 10.43 (-0.12), QQQ: 103.26 (+0.80), AOL: 46.39 (+0.55), BABA: 117.50 (-0.70)

Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker  Allergan   is desperately trying to fend off a takeover bid from  Valeant Pharmaceuticals  , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.66 (+1.15), VRX: 133.65 (+2.56), ACT: 244.26 (+3.64)

Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST

AGN: 197.66 (+1.15), ZTS: 43.14 (+0.50), ACT: 244.26 (+3.64), VRX: 133.65 (+2.56)

Zoetis jumps 6% on report of Ackman stake
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 2:48PM CST

ZTS: 43.14 (+0.50), VRX: 133.65 (+2.56)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.83 (-0.06), AGN: 197.66 (+1.15), ACT: 244.26 (+3.64), VRX: 133.65 (+2.56), MDT: 69.51 (+1.01), SLXP: 96.62 (+1.07), SNY: 46.88 (+0.32)

Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.28 (+0.57), VRX: 133.65 (+2.56), ALXN: 194.38 (+0.69), AMGN: 161.54 (-0.39), MYL: 56.04 (+2.24), ILMN: 189.98 (+3.06), CELG: 108.70 (+0.45)

Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 197.66 (+1.15), VRX: 133.65 (+2.56), AUXL: 32.51 (-0.01), SLXP: 96.60 (+1.05)

Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 133.65 (+2.56), VRX.TO: 151.62 (+2.65)

Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 197.66 (+1.15), VRX: 133.65 (+2.56), DVA: 76.98 (+0.26), GILD: 105.02 (-1.88), SLXP: 96.60 (+1.05), ICPT: 159.60 (-3.36), HUM: 139.04 (+1.79)

These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 197.66 (+1.15), VRX: 133.61 (+2.52), HHC: 145.58 (-0.03), PAH: 25.23 (+0.33), CP: 208.07 (+0.26), APD: 135.71 (+0.92), BKW: 32.15 (+0.03)

Earnings Pulse - Valeant Pharma Intl.
PR Newswire - Fri Nov 07, 8:10AM CST
Investor-Edge.com has issued free earnings review on Valeant Pharmaceuticals International Inc. (NYSE: VRX). On October 20, 2014, the company reported its financial results for Q3 FY14 (period ended September 30, 2014). Click on www.investor-edge.com/FreeReports to read our free earnings review on Valeant Pharmaceuticals International Inc. (Valeant). During Q3 FY14, the pharmaceutical company's net revenue grew 33% on a Y-o-Y basis and its cash EPS saw an increase of 48% from the preceding year quarter. Our free coverage report can be accessed at:
VRX: 133.61 (+2.52)

Valeant Pharmaceuticals International Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 06, 3:58PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $128.38 to a high of $132.79. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $130.03 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 133.61 (+2.52)

Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 46.81 (-0.67), TSLA: 254.24 (+5.14), VRX: 133.61 (+2.52), KR: 58.50 (+0.12), UN: 39.40 (+0.54), UTX: 108.86 (+0.72), PFE: 30.61 (+0.19), HAL: 51.83 (-1.40), TAP: 76.37 (+1.01), KORS: 71.48 (+0.48), TLT: 118.61 (-0.02), PEP: 98.65 (+1.49), DFS: 65.63 (-0.38), COH: 34.98 (-0.18), SPY: 204.81 (+0.85), QQQ: 103.26 (+0.80), QCOM: 70.77 (+0.48), DIA: 176.97 (+0.93), COST: 138.16 (+1.26), IWM: 118.01 (+0.11), MSFT: 49.44 (+0.66), CBS: 52.43 (+0.86)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 192

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 134

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 104

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 231

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Joshua Davenport: Celebrating 25 Years in Healthcare

Updated Category News Views 113

25 Years Strong: Davenport's Journey in Healthcare Not every day you celebrate someone who's spent a quarter of a century in the trenches of healthcare. Joshua L. Davenport, RN, isn't just clocking years; he's built a legacy in emergency nursing and occupational health that speaks volumes about resilience and commitment to others. From Humble Beginnings to Health...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 98

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Denarius Metals Unveils Technical Insight for Toral Project

Updated Category News Views 44

Denarius Metals Shares Tech Report on Toral Project It's a curious moment in the mining world when Denarius Metals decides to drop their latest gem—a technical report on the Toral Project. We're talking about a full-bodied document rooted in the stringent National Instrument 43-101 standards. This isn't some half-baked release; it's a robust assertion of where they...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 203

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading
NEXT Properties Exchange Offers: The Full Breakdown

Updated Category News Views 163

What's the Deal with These Exchange Offers? You know, nothing says 'we're changing things up' like an exchange offer. So what did NEXT Properties do? Well, they laid down two offers for the books on their outstanding 6.950% and 6.390% senior notes, due in 2044 and 2050, respectively. These are getting swapped out for some fresh 7.731% senior sustainability-linked notes...

Continue Reading
DigitalXForce Booms with 514% Growth and Major Backing

Updated Category News Views 204

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...

Continue Reading

Top 5 Most Recently Viewed Articles

Haven Tower Elevates Leaders for Strategic Expansion

Updated Category News Views 6

When a company starts moving its chess pieces around, savvy investors know it's time to pay attention. Haven Tower Group, a heavyweight in strategic communications for the wealth management realm, is shaking things up. They've promoted Mitch Manning to Chief Engagement Officer & Partner and brought on Grant Cox as Principal. These moves aren't just about office...

Continue Reading
CoStar Group Set to Release Q4 and Full Year 2024 Results

Updated Category News Views 205

CoStar Group Plans to Announce Financial Outcomes CoStar Group, Inc. (NASDAQ: CSGP), a prominent leader in online real estate marketplaces and analytics, is gearing up to present its financial results for the fourth quarter and the entirety of the 2024 fiscal year. The announcement will take place following the market's closing on a specified Tuesday, during which...

Continue Reading
Disc Medicine's Participation in Key Investor Conferences

Updated Category News Views 97

Disc Medicine to Participate in Key Investor Conferences Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, is setting the stage for crucial engagements with investors. The company focuses on the discovery, development, and commercialization of innovative treatments aimed at patients facing serious hematologic...

Continue Reading
Bollinger Motors Celebrates First B4 Truck Deliveries Ahead

Updated Category News Views 50

Bollinger Motors delivered its first B4 electric trucks to Nacarato Truck Centers back in September 2024, marking an important step in their operational journey. This deal was worth a solid $800,000—a number that certainly turned heads among desks tracking EV trends. The delivery set the stage for what traders hoped would be a stream of revenue as Bollinger established...

Continue Reading
Nasdaq Achieves Significant Growth and Future Predictions

Updated Category News Views 191

Revenue Highlights from Nasdaq's Latest Report Nasdaq, Inc. (NASDAQ:NDAQ) recently revealed impressive financial results, showcasing a remarkable revenue increase of 15% compared to the previous year, totaling $1.315 billion. This was a better outcome than analysts had anticipated, with expectations set at $1.297 billion. Strong Adjusted Earnings The financial services...

Continue Reading